Browsing by Author "Jose Peña"

Now showing 1 - 1 of 1
  • No Thumbnail Available
    Item
    The neutrophil to lymphocyte ratio predicts the response to neoadjuvant chemotherapy in luminal B breast cancer
    (2019) Mauricio Rivas; Francisco Acevedo; Francisco Dominguez; Hector Galindo; Mauricio Camus; David Oddo; Alejandra Villarroel; Dravna Razmilic; Jose Peña; Matias Munoz Medel; Maria Elena Navarro; Alejandra Perez-Sepulveda; Lidia Medina; Tomas Merino; Juan Briones; Alexis Kalergis; Cesar Sanchez
    Objective: Tumor response to neoadjuvant chemotherapy (NAC) in breast cancer (BC) patients is a predictor for overall survival. The aim of our study was to determine a relationship between the neutrophil to lymphocyte ratio (NLR) prior to NAC, BC subtypes and the probability of a pathologic complete response (pCR). Materials and Methods: Medical records were collected retrospectively from Centro de Cancer at Red Salud UC-Christus. Clinical data collected included peripheral blood cell counts, BC subtype at diagnosis and the pathology report of surgery after chemotherapy. Results: A total of 88 patients were analyzed. Approximately, a 25% had a pCR, and displayed a significant correlation between BC subtype and pCR (p= 0.0138 Chi2); this was more frequent in epidermal growth factor receptor type 2 (HER2) enriched subtype patients (54%). Luminal B BC patients with a pCR had significantly lower NLR levels (t test, p= 0.0181). Conclusions: HER2-enriched tumors had a higher probability of pCR. In Luminal B tumors, NLR had a statistically significant relationship with the probability of pCR. In this subtype, NLR could be a useful biomarker to predict tumor response to NAC. Further studies including other clinical parameters for systemic inflammation such as platelet counts, intratumoral NLR or body mass index could help identify patients that would get the most benefit from NAC.